Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Development of a Novel Bio-Adhesive Mesh System for Abdominal Hernia Repair

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 300

    Development of a Novel Bio Adhesive Mesh System for Abdominal Hernia Repair Project Summary Abstract This project proposes the development of a novel mesh adhesive system for abdominal hernia repair utilizing surface modification of polymer surgical mesh to allow for improved tissue fixation with a poloxamine hydrogel adhesiveMore thanmillion Americans undergo hernia repair with surgical mesh each ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing and validating a podocyte cell-based diagnostic assay for identifying recurrent focal and segmental glomerulosclerosis patients

    SBC: InDepth Pharmaceuticals, LLC            Topic: 400

    Diagnosing glomerular diseases accurately and in timely fashion is key to developing a successful treatment plan and thereby prevent their progression to ESRDend stage renal diseaseHowevertheir successful diagnosis remains challenging due to the complex diagnostic procedures used including invasive renal biopsiesThusthere is a compelling need to develop simplified procedures to detect glomerular d ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp toof low birth weight preterm infants manifest some form of periventricular white matter injuryPWMImaking it the most common form of brain injury affecting premature infantsPWMI is associated with significant morbidityas affected individuals may have profound intellectual impairment and cerebral palsyHighlighting the magnitude of PWMIeach year more thaninfants are born prematurely in th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution

    SBC: SGgenomics, Inc.            Topic: 101

    PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Stem Cell-derived Cell-free Therapeutic for Stress Urinary Incontinence

    SBC: NeuroFx, Inc.            Topic: 400

    Abstract Stress urinary incontinenceSUIcan result from a combinatorial neuromuscular injury to the pudendal nerve and the muscle it innervatesthe external urethral sphincterEUScompounded by the biochemical effects of agingThe mechanisms of SUI development include incomplete pudendal nerve regeneration and EUS sphincter repair from the maternal polytrauma of childbirth as well as biochemical change ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Chelation for Reversal of Vascular Calcification

    SBC: Elastrin Therapeutics Inc.            Topic: NHLBI

    PROJECT SUMMARY Medial arterial calcification is a form of vessel hardening in which calcium deposits are found in the medial layer of elastic and muscular arteriesspecifically on elastic fibersleading to arterial stiffening and tearingAn independent risk factor for cardiovascular diseases in diabetic and chronic kidney disease patientsit predisposes the patients to cardiovascular mortality and lo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury

    SBC: Lydex Pharmaceuticals LLC            Topic: 300

    Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Novel Therapeutic for Hyperthyroidism

    SBC: Medosome Biotec, LLC            Topic: NIDDK

    GravesdiseaseGDis the most common cause of hyperthyroidism and is caused by stimulation of the thyroid stimulating hormone receptorTSHRby thyroid receptor stimulating antibodiesTSAbsTreatment of GD involves antithyroid medication therapyradioactive iodineand surgeryAt the presentfew alternative forms of therapy for GD are available or are in developmentThe ability to block TSHR action may also be ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of the GlycoFibrotyper for detection of liver fibrosis

    SBC: GlycoPath, LLC            Topic: 300

    Increasinglyalterations in N linked glycans have been reported for serum or plasmaor for the most abundant serum glycoproteinimmunoglobulin Gfrom large cohorts of samples representing rheumatoid arthritisdigestive diseasescancer and liver fibrosisIn the case of fibrosistwo tests have identified alterations in Nlinked glycosylation on both total IgG populations and on specific IgG moleculesBoth of ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ototoxici ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government